Herpes Zoster Virus Archives - Dermatology Advisor

Case Study: Herpes Zoster in Patients With MS Treated With Dimethyl Fumarate

By

Jessica Nye, PhD

July 20, 2021

This case study examines 2 patients with relapsing remitting multiple sclerosis, under dimethyl fumarate treatment, who developed severe herpes zoster infection.

Dermatitis

Upadacitinib Plus Topical Corticosteroids an Option in Adult, Adolescent Dermatitis

By

Brandon May

July 14, 2021

The efficacy and safety of combined upadacitinib and topical corticosteroid therapy for the treatment of atopic dermatitis was evaluated.

General Dermatology

Lyme Disease May Be Associated With Genital Lesions and Morgellons Disease

By

Colby Stong

July 6, 2021

The case of a 49-year old woman with erosive genital ulcerations, rashes, and skin lesions associated with Lyme disease is reviewed.

General Dermatology

Anifrolumab Improves Skin and Joint Disease Activity in Patients With Systemic Lupus Erythematosus

By

Bradley van Paridon

June 22, 2021

According to data from a press release, which were later presented at the EULAR 2021 Virtual Congress, “Anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures…in patients with moderate to severe SLE.”

Infections

Can Face Touching Improve Ocular Health?

By

Jodi McCaffrey, MA, FACHE

June 17, 2021

Investigators ask if developing microbiome from face touching can protect against foreign and opportunistic pathogens.

Risk of stroke after herpes zoster in patients with autoimmune diseases

General Dermatology

Herpes Zoster in Immunocompetent Patients Raises Risk for Complications

By

Estie Mermelstein, MSN, FNP-BC

June 8, 2021

The complications associated with immunocompromised patients with herpes zoster was examined.

No single treatment for HS is effective in eradicating disease or preventing progression, but early recognition and treatment are critical to preventing further progression to severe disease that can have an impact on quality of life.8 Therapeutic goals for stage 1 HS in young patients are to reduce pain and inflammation and prevent scarring and disease progression through multimodal management. Topical disinfectants are generally considered ineffective.4 Topical antibiotics are the therapy of choice for mild-to-moderate disease, with the introduction of oral antibiotics where topical formulations are inadequate.4 Once the disease has progressed, biologic disease modifying antirheumatic therapies, laser therapy, and surgery may have some benefit.8 Evidence supporting the use of intravenous infliximab in Hurley stage 2 and 3 HS has not been adequate enough to recommend it.9 Treatment of HS requires an aggressive multidisciplinary effort that involves antibiotic treatment, multimodal anti-inflammatory therapy and hormonal therapies, dietary and lifestyle modifications, and avoidance of physical trauma to the affected regions, which can lead to rupture of abscesses, along with early surgical unroofing and debridement. Additionally, because of the stigma and psychological distress, counseling for possible depression and to support coping skills is also recommended.3

General Dermatology

Evidence-Based Comorbidity Screening for Patients With Hidradenitis Suppurativa

By

Brandon May

March 31, 2021

To improve long-term outcomes for patients with HS, evidence-based screening recommendations to help clinicians recognize and treat 30 comorbid conditions have been developed.